Oxytocin: what the research shows
- By Reed Calder
- Last reviewed Nov 15, 2026
- 40 studies and official documents checked
In short
Oxytocin is a peptide hormone of nine amino acids, made in the hypothalamus and released by the pituitary gland. It makes the uterus contract in labor and moves milk during nursing, and it acts in the brain. It is also an FDA-approved injection, sold as Pitocin and under its generic name, for starting labor when there is a medical reason and for controlling bleeding after birth. It is given by vein in a hospital.
The oxytocin sold as a nasal spray for mood, bonding, weight loss or sex drive is a different story. The FDA lists no nasal oxytocin product, and its oxytocin applications are all injections. Human trials of the nasal spray are real, but the largest were not positive: in 290 children and teenagers with autism, 24 weeks of spray did no better than placebo (p = 0.61), and in 61 adults with obesity, 8 weeks of spray did not change weight (0.20 against 0.26 kg, p = 0.934).
A 2026 analysis of 42 trials in mental disorders found a small effect that was not statistically significant. The finding that oxytocin raises trust has not replicated well, and how much of a nasal dose reaches the brain is still argued. Short trials report side effects no different from placebo, but the injection’s label warns of water intoxication, and a 1985 case report describes seizures after heavy use of a nasal spray.
EvidenceCellAnimalHumanrandomized trials of the nasal spray with mixed results; the largest were negative
You’ll often read that oxytocin is the love or trust hormone, that a nasal spray eases anxiety, treats autism, helps you lose weight and improves sex, and that it has no side effects. This page covers what oxytocin is, what the trials of the nasal spray found, what the approved injection does, how much reaches the brain, safety, and where it stands with the FDA.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Oxytocin | The natural peptide hormone, nine amino acids with a sulfur bridge between two of them, also made in the lab (PubChem CID 439302) | Yes: by vein, by muscle injection and as a nasal spray |
| Pitocin, oxytocin injection | FDA-approved injections of synthetic oxytocin for labor and for bleeding after birth. The FDA lists three oxytocin applications, Pitocin and two others, all injections (openFDA Drugs@FDA; Pitocin label) | Yes: the approved uses, and trials of other uses by vein |
| Syntocinon, intranasal oxytocin, oxytocin nasal spray | Oxytocin sprayed into the nose. Syntocinon is the brand name several research trials list; the FDA lists no nasal oxytocin product (openFDA Drugs@FDA) | Yes: most trials of oxytocin for behavior, mood and weight |
| Oral, lingual or oromucosal oxytocin | Oxytocin sprayed under the tongue or in the mouth, or dissolved from a lollipop-style product | Three registered trials in healthy adults, listed below; no results yet |
| Carbetocin | A different drug: an oxytocin analogue with a longer half-life and greater receptor selectivity (Roof et al., 2026). It was compared with oxytocin to prevent bleeding after birth (Widmer et al., 2018) | Not covered here beyond those comparisons |
| “Oxytocin” homeopathic products | The FDA’s drug-listing data include 16 oral products labeled unapproved homeopathic that name oxytocin (openFDA NDC) | We did not look for studies of them |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The number below is for oxytocin itself; carbetocin has its own.
| Form | CAS number | Registry record |
|---|---|---|
| Oxytocin | 50-56-6 | PubChem |
What oxytocin is
Oxytocin is a peptide hormone and a neuropeptide. The hypothalamus makes it and the posterior pituitary gland stores and releases it. It weighs 1,007.2 g/mol (PubChem CID 439302).
In the blood it works as a hormone, controlling milk letdown and uterine contraction and cervical dilation in birth. In the brain it acts as a neurotransmitter on areas tied to social, behavioral and motivational states (Wudarczyk et al., 2013).
The “love hormone” nickname comes from animal work. In prairie voles, giving oxytocin to females and vasopressin to males strengthened pair bonding without mating. The same review says it has not been shown conclusively that human attachment runs on the same machinery (Wudarczyk et al., 2013).
Oxytocin leaves the blood fast. After a 24 IU nasal dose in 11 people, blood levels peaked about 15 minutes later and fell by 75 minutes, while spinal fluid levels took up to 75 minutes to rise significantly (Striepens et al., 2013). It also makes the kidneys hold water: the FDA label describes an intrinsic antidiuretic effect (Pitocin label).
What has been studied
Nasal oxytocin in autism
| Study | Who | What was used | What it found |
|---|---|---|---|
| Sikich et al., 2021 (SOARS-B) | 290 children and teenagers aged 3 to 17 with autism (146 oxytocin, 144 placebo); randomized, placebo-controlled, phase 2, 24 weeks | Nasal oxytocin, target total dose 48 IU a day, or placebo | Change on the social withdrawal scale was -3.7 with oxytocin and -3.5 with placebo (difference -0.2, 95% CI -1.5 to 1.0; p = 0.61). Secondary outcomes generally didn’t differ, and adverse events were similar |
| Guastella et al., 2023 | 87 children aged 3 to 12 with autism (45 oxytocin, 42 placebo); double-blind, after a 3-week placebo lead-in | Oxytocin nasal spray, 16 IU morning and night for 12 weeks, or placebo | No overall effect on caregiver-rated social responsiveness (p = 0.686). Children aged 3 to 5 showed some sign of benefit on that scale (age interaction p = 0.028), but not on the clinician-rated scale or any secondary measure. More adverse events were reported with placebo |
| Yatawara et al., 2016 | 31 young children with autism; randomized, placebo-controlled crossover | Nasal spray, 12 IU of oxytocin or placebo morning and night for 5 weeks each, with a 4-week washout | Better caregiver-rated social responsiveness with oxytocin. The most common adverse events were thirst, urination and constipation |
| Daniels et al., 2023 | 77 children aged 8 to 12 with autism (61 boys, 16 girls); double-blind, then a single-blind phase | Nasal oxytocin, 12 IU twice a day for 4 weeks, or placebo | Both groups improved in the double-blind phase, and the gains weren’t specific to oxytocin. After the switch to oxytocin, the former placebo group improved further |
| Cai et al., 2018 | 5 randomized trials, 223 people (123 oxytocin, 100 placebo); meta-analysis of side effects | Long-term nasal oxytocin against placebo | Nasal discomfort 14.3%, irritability 9.0%, tiredness 7.2%, diarrhea 4.5% and skin irritation 4.5%; none was linked to treatment. Five severe events: aggression (1 placebo, 2 oxytocin) and seizures (1 and 1) |
| Huang et al., 2021 | 28 studies, 726 people with autism, including uncontrolled studies; meta-analysis | Nasal oxytocin | Benefits on social functioning; no strong sign of benefit for symptoms outside the social domain |
The two largest trials, 290 and 87 children, found no overall benefit. The trials with gains were smaller, and in the 77-child trial parents rated both groups as improved during the blinded phase. Whether a benefit exists in the youngest children is raised by one trial and not settled.
EvidenceCellAnimalHumanrandomized trials in children; the largest found no benefit
Nasal oxytocin in schizophrenia, anorexia and other conditions
| Study | Who | What was used | What it found |
|---|---|---|---|
| Bonnieux et al., 2026 | 42 double-blind randomized trials, 1,922 people, in autism, schizophrenia spectrum, substance use and other mental disorders; meta-analysis | Nasal oxytocin or placebo | A small, non-significant overall effect (g = 0.17, 95% CI -0.05 to 0.38) with large differences between trials. Without two outlier trials in substance use disorders, g = 0.05 (-0.03 to 0.12). In schizophrenia spectrum disorders a small effect (g = 0.12, 0.01 to 0.23). No significant effect of dose or number of doses; after removing outliers, trials with more women showed larger effects |
| Sabe et al., 2021 | 9 randomized trials in schizophrenia; meta-analysis | Nasal oxytocin for negative symptoms | No significant effect overall. A moderate effect appeared at doses above 40 to 80 IU, then disappeared when one outlier study was removed |
| Maguire et al., 2024 | 61 women in hospital with anorexia nervosa; randomized, placebo-controlled phase 2 | Nasal oxytocin, 18 IU twice a day for 4 weeks during refeeding, or placebo | No difference from placebo on eating disorder measures or BMI at any point, including 6 months later, and no effect on anxiety or cortisol after a snack |
Trials of oxytocin added to therapy for PTSD, borderline personality disorder and schizophrenia are registered and recruiting; they are listed below under trials under way.
EvidenceCellAnimalHumana small, non-significant average effect across 42 trials
Weight, appetite and muscle
| Study | Who | What was used | What it found |
|---|---|---|---|
| Plessow et al., 2024 | 61 adults with obesity (54% women, mean age 33.6); randomized, placebo-controlled | Nasal oxytocin, 24 IU four times a day for 8 weeks, or placebo | Weight change was 0.20 against 0.26 kg (p = 0.934), with no benefit on fat, liver fat or resting energy use. Calories eaten at a test meal fell by 31.4 against a rise of 120.6 (difference -152.0 kcal, 95% CI -302.3 to -1.7). No serious adverse events |
| Chen et al., 2021 | 12 controlled trials: 266 people without psychiatric conditions and 157 with; meta-analysis | A single nasal dose of oxytocin | Less food eaten in people without psychiatric conditions (SMD -0.66, 95% CI -1.18 to -0.14); no effect in anorexia nervosa, bulimia, binge eating or schizophrenia, and none on craving, hunger, anxiety or stress |
| Espinoza et al., 2021 | 21 older adults with obesity and slow walking (mean age 67.5); pilot, randomized, placebo-controlled | Nasal oxytocin, 24 IU four times a day for 8 weeks | Whole-body lean mass rose 2.25 kg compared with placebo (p < .01) and LDL cholesterol fell 19.3 mg/dL (p = .023). No change in BMI, appetite, blood sugar, HDL or triglycerides. No significant adverse events |
| Galbiati et al., 2026 | The same 61 adults as the obesity trial above | Nasal oxytocin, 24 IU four times a day for 8 weeks | No change in prolactin or sex hormones (p of 0.140 or more) or in menstrual cycle length (p = 0.234), which the authors call preliminary support for reproductive safety |
EvidenceCellAnimalHumanthe largest trial found no weight loss; one 21-person pilot found muscle and cholesterol changes
Sex, desire and relationships
| Study | Who | What was used | What it found |
|---|---|---|---|
| Kruger et al., 2018 | 27 healthy women (mean age 27.5); double-blind crossover in a lab | Nasal oxytocin, 24 IU | No effect on sexual drive, arousal, orgasm or vaginal blood flow; one measure of tension after orgasm was close (p = 0.051) |
| Behnia et al., 2014 | 29 healthy couples (58 people); naturalistic, double-blind | Nasal oxytocin, 24 IU | No change in sexual drive, arousal, erection or lubrication. Orgasm intensity and contentment after intercourse rose, with small to moderate effect sizes and more in men |
| Muin et al., 2017 | Male partners of 30 women with low sexual desire who were in a randomized trial; open cohort | The women used a 32 IU oxytocin spray or placebo before intercourse for 8 weeks each | Men’s sexual quality of life improved with both oxytocin and placebo, and the two didn’t differ on any outcome |
| Schneider et al., 2026 | 80 healthy heterosexual couples (160 people); randomized, placebo-controlled | Oxytocin or placebo twice a day for 7 days, with or without a structured appreciation task | Wounds healed faster in couples who did the task and got oxytocin (p = .048), but not consistently in a sensitivity analysis (p = .10). Oxytocin plus daily affectionate touch or sexual activity was linked to smaller wounds |
EvidenceCellAnimalHumansmall trials in healthy people; no result in people with sexual dysfunction beyond one cohort
Trust and favoritism toward your own group
A critical review concluded that the simplest promising finding, that nasal oxytocin raises trust, “has not replicated well,” that blood measures of oxytocin are flawed, and that large genetic studies found no consistent link between oxytocin-related genes and trust (Nave et al., 2015). In five placebo-controlled experiments in men, oxytocin motivated favoritism toward the participant’s own group and, to a lesser extent, derogation of outsiders (De Dreu et al., 2011).
EvidenceCellAnimalHumanlab experiments in healthy volunteers, mostly men
Pain and nursing
| Study | Who | What was used | What it found |
|---|---|---|---|
| Boll et al., 2020 | 22 men with chronic low back pain and 22 healthy men; exploratory randomized crossover with brain scans | Nasal oxytocin or placebo | Heat-pain ratings fell in the patients compared with the healthy men; no effect on spontaneously occurring back pain |
| Flynn et al., 2021 | 21 women with chronic pelvic pain randomized, data from 12 usable; crossover feasibility study | A 2-week course of nasal oxytocin or placebo | Pain severity improved with no effect on pain interference. Four women reached a clinically meaningful improvement on oxytocin and none on placebo. Adverse effects didn’t differ |
| Fewtrell et al., 2006 | 51 mothers expressing milk for preterm infants (27 oxytocin, 24 placebo); double-blind | Oxytocin nasal spray before pumping, up to day 5 | Total milk output didn’t differ. Output rose faster at first with oxytocin, then the groups converged. Most mothers believed they had the active spray, which the authors read as a strong placebo effect |
EvidenceCellAnimalHumansmall and exploratory
Does a nasal spray reach the brain?
| Study | Who | What was used | What it found |
|---|---|---|---|
| Striepens et al., 2013 | 15 people: 11 got oxytocin and 4 placebo; blood and spinal fluid sampling | Nasal oxytocin, 24 IU | Oxytocin rose in both blood and spinal fluid. Blood peaked at 15 minutes and spinal fluid took up to 75 minutes. The two weren’t correlated (r below 0.10) |
| Lee et al., 2018 | 6 rhesus macaques | Labeled oxytocin, 80 IU, by nose or by vein, and nasal saline | Labeled oxytocin reached spinal fluid by both routes. The nasal route gave no advantage over the vein, and peripheral dosing didn’t trigger release of the animals’ own oxytocin |
| Lee et al., 2020 | Rhesus macaques | Labeled oxytocin by nose or by vein; brain tissue measured 2 hours later | Labeled oxytocin was found in several brain regions after the nasal dose but not after the intravenous dose |
| Valstad et al., 2017 | 17 studies, 516 people; meta-analysis of central and peripheral levels | Spinal fluid and blood oxytocin measured together | Overall correlation r = 0.29. None at baseline (r = 0.08); strong after a nasal dose (r = 0.66) and after stress (r = 0.49) |
| Leng and Ludwig, 2016 | A review of the evidence | Nasal oxytocin | Argues that very little of a nasal dose appears to reach spinal fluid, while blood levels rise above normal with likely effects on the gut, heart and reproductive tract |
So there is evidence in both directions: oxytocin does show up in human spinal fluid after a nasal dose and in macaque brain tissue, and a review argues the amounts are small and that effects in the body, not the brain, may explain some results.
EvidenceCellAnimalHumansmall human study; macaque data; reviewers disagree
The approved use: labor and bleeding after birth
| Study | Who | What was used | What it found |
|---|---|---|---|
| Flanagan et al., 2026 | 14 eligible randomized trials; 4 shared individual data (4,304 women); meta-analysis | Oxytocin by injection against placebo or no treatment after birth | Oxytocin cut the risk of bleeding of 500 mL or more (adjusted odds ratio 0.59, 95% CI 0.46 to 0.74) and of 1,000 mL or more (0.51, 0.32 to 0.80). In the trials judged trustworthy (6,003 women) the odds ratios were 0.53 and 0.59 |
| Gallos et al., 2025 | 122 trials, 121,931 women; Cochrane network meta-analysis | Seven uterotonic drugs against each other, placebo or no treatment | Every agent except injectable prostaglandins prevented bleeding of 500 mL or more compared with placebo or none. Compared with oxytocin, ergometrine plus oxytocin (risk ratio 0.76) and misoprostol plus oxytocin (0.70) reduced bleeding of 500 mL or more, and carbetocin had a similar effect. The WHO recommends oxytocin for prevention |
| Widmer et al., 2018 | 29,645 women having vaginal births, 23 sites in 10 countries; randomized, double-blind, noninferiority | Heat-stable carbetocin 100 mcg or oxytocin 10 IU, by muscle injection after birth | Blood loss of 500 mL or more, or extra drugs: 14.5% with carbetocin and 14.4% with oxytocin (relative risk 1.01, 0.95 to 1.06). Blood loss of 1,000 mL or more: 1.51% and 1.45%; noninferiority was not shown for that outcome because events were rare |
EvidenceCellAnimalHumanlarge randomized trials and meta-analyses; this is the approved use
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Oxytocin is the love hormone that makes you trust | Mixed | Oxytocin is tied to birth, nursing and bonding in animals, but the nasal-spray finding that it raises trust has not replicated well, and in men it increased favoritism toward their own group (Nave et al., 2015; De Dreu et al., 2011) |
| A nasal spray treats autism | Mixed | The largest trial (290 children, 24 weeks) found no difference from placebo (p = 0.61), and an 87-child trial found none overall; two smaller trials and a meta-analysis that included uncontrolled studies found gains on parent-rated social scales (Sikich et al., 2021; Guastella et al., 2023; Yatawara et al., 2016; Huang et al., 2021) |
| It treats schizophrenia, anorexia or other mental disorders | Mixed | A 2026 meta-analysis of 42 trials found a small, non-significant overall effect and a small effect in schizophrenia spectrum disorders; a 61-woman anorexia trial found no difference from placebo (Bonnieux et al., 2026; Maguire et al., 2024) |
| It lowers stress and anxiety | Mixed | Early lab studies reported lower stress responses (as described in a 2013 review), but a meta-analysis of single-dose trials found no change in anxiety or stress in any group, and the anorexia trial found none (Wudarczyk et al., 2013; Chen et al., 2021; Maguire et al., 2024) |
| It helps you lose weight | Contradicted | In 61 adults with obesity, 8 weeks of nasal oxytocin did not change weight (0.20 against 0.26 kg, p = 0.934) or body fat, and a pilot in older adults saw no change in BMI (Plessow et al., 2024; Espinoza et al., 2021) |
| It cuts appetite | Mixed | Single doses reduced the food eaten in people without psychiatric conditions (SMD -0.66), and test-meal calories were 152 kcal lower in the obesity trial, but craving and hunger didn’t change and there was no effect in eating disorders (Chen et al., 2021; Plessow et al., 2024) |
| It boosts sex drive and sexual function | Mixed | No effect on drive, arousal or vaginal blood flow in 27 women; a couples trial found no change in drive or arousal but higher orgasm intensity, with small to moderate effects; in a trial for low desire, men’s ratings improved equally with oxytocin and placebo (Kruger et al., 2018; Behnia et al., 2014; Muin et al., 2017) |
| It heals wounds faster | Mixed | One trial of 80 couples found faster healing in couples who also did a positive-interaction task (p = .048), but the result was not consistent in a sensitivity analysis (p = .10) (Schneider et al., 2026) |
| It lowers LDL cholesterol and builds muscle | Mixed | One pilot of 21 older adults found 2.25 kg more lean mass and 19.3 mg/dL lower LDL after 8 weeks; we found no larger trial that measured either (Espinoza et al., 2021) |
| It slows aging | Untested | We found no trial in people that measured oxytocin against aging markers |
| A nasal spray gets oxytocin into the brain | Mixed | Oxytocin rose in human spinal fluid after a nasal dose and reached macaque brain tissue, but the human rise didn’t track blood levels, the nasal route had no advantage over a vein in macaque spinal fluid, and a review argues little reaches it (Striepens et al., 2013; Lee et al., 2020; Lee et al., 2018; Leng and Ludwig, 2016) |
| An oxytocin injection starts labor and controls bleeding after birth | Supported | Yes. It is the FDA-approved use, and an individual-data meta-analysis found oxytocin cut bleeding of 500 mL or more (adjusted odds ratio 0.59) and of 1,000 mL or more (0.51) (Pitocin label; Flanagan et al., 2026) |
| Nasal oxytocin is FDA-approved | Contradicted | No. Drugs@FDA lists three oxytocin applications and all are injections; the Pitocin label covers intravenous use in a hospital (openFDA Drugs@FDA; Pitocin label) |
| Oxytocin has no side effects | Mixed | Short nasal-spray trials reported side effects no different from placebo, but the injection’s label warns of water intoxication, and a 1985 case report describes water intoxication with convulsions after heavy nasal-spray use (MacDonald et al., 2011; Pitocin label; Seifer et al., 1985) |
| Oxytocin products sold online or compounded are pure and tested | Untested | We found no analysis of nasal oxytocin products sold online or compounded. A review of oxytocin injections in low- and middle-income countries found a median of 45.6% of samples failed quality tests (Torloni et al., 2016) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Sikich et al., 2021 | Autism, 24 weeks | Nasal oxytocin, target total dose 48 IU a day |
| Guastella et al., 2023; Yatawara et al., 2016; Daniels et al., 2023 | Autism in young children | Nasal spray, 12 to 16 IU twice a day for 4 to 12 weeks |
| Maguire et al., 2024 | Anorexia nervosa | Nasal oxytocin, 18 IU twice a day for 4 weeks |
| Plessow et al., 2024; Espinoza et al., 2021 | Obesity and sarcopenic obesity | Nasal oxytocin, 24 IU four times a day for 8 weeks |
| Kruger et al., 2018; Behnia et al., 2014; Striepens et al., 2013 | Sexual function, brain delivery | Nasal oxytocin, 24 IU once |
| Muin et al., 2017 | Low sexual desire (partners’ ratings) | Nasal spray, 32 IU before intercourse |
| Lee et al., 2018 | Brain delivery in macaques | Labeled oxytocin, 80 IU, by nose or by vein |
| Widmer et al., 2018 | Bleeding after birth | Oxytocin 10 IU by muscle injection once, against carbetocin 100 mcg |
| MacDonald et al., 2011 | Review of research trials | Mostly single doses of 18 to 40 IU, up to 182 administrations |
IU means international units, a measure of potency, not weight. Nasal doses in research were sprays in each nostril, given in a clinic or by a research team. Hospital dosing for labor is set by obstetric protocols and isn’t covered here, and nothing on this page is a dosing recommendation.
Side effects and safety
- In the nasal-spray trials. A review of 38 randomized trials (1,529 people, 79% of them men) found side effects no different from placebo at 18 to 40 IU in short use, and three case reports of adverse reactions from misuse or longer use (MacDonald et al., 2011). In autism trials, nasal discomfort, irritability, tiredness, diarrhea and skin irritation were reported, with none linked to treatment (Cai et al., 2018). The 290-child trial found similar adverse events in both groups (Sikich et al., 2021), and the 61-adult obesity trial had no serious ones (Plessow et al., 2024).
- Water intoxication. Oxytocin makes the kidneys hold water. The FDA label warns of water intoxication, particularly with continuous infusion in someone drinking fluids, and lists severe cases with convulsions and coma, including a maternal death (Pitocin label). In 1985 a nursing mother developed severe water intoxication and seizures after excessive, unmonitored use of a nasal spray while also given a large amount of intravenous fluid; the authors judged the spray the likely cause (Seifer et al., 1985).
- The approved injection. The label lists situations where antepartum use is contraindicated, including fetal distress where delivery is not imminent and an already overactive uterus, and says excessive dosage can cause uterine spasm or rupture. For induction or augmentation of labor it is given only by vein, with adequate medical supervision in a hospital (Pitocin label).
- Behavior. In men, oxytocin increased favoritism toward their own group (De Dreu et al., 2011). A 2013 review lists envy and less trust in people with borderline personality disorder among the findings (Wudarczyk et al., 2013).
- Effects in the body. A review argues nasal dosing raises blood levels above normal, with likely effects on the gut, heart and reproductive tract (Leng and Ludwig, 2016). In the 61-adult trial, 8 weeks didn’t change prolactin, sex hormones or menstrual cycle length (Galbiati et al., 2026).
- Product quality. In 8 studies of 559 oxytocin injection samples from 15 low- and middle-income countries, a median of 45.6% failed quality tests, mostly for too little active ingredient (Torloni et al., 2016). We found no analysis of nasal products.
- Not known. Long-term safety of nasal oxytocin, safety in pregnancy outside the approved injection, and effects in women, since most research volunteers were men. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- Approved as an injection. Drugs@FDA lists three oxytocin applications, NDA018248, NDA018261 (Pitocin) and ANDA200219, all injectable (openFDA Drugs@FDA). The Pitocin label, effective May 6, 2026, covers inducing labor where there is a medical reason, stimulating or reinforcing labor, adjunct treatment of incomplete or inevitable abortion, and, after birth, producing contractions in the third stage and controlling bleeding. It says Pitocin is not indicated for elective induction of labor (Pitocin label).
- No approved nasal product. The label doesn’t mention nasal use, and Drugs@FDA lists no nasal oxytocin. The FDA’s drug-listing data show 60 listings that name oxytocin: 11 approved injections, 29 bulk-ingredient powders, 3 powders labeled for human prescription compounding, 16 oral products labeled unapproved homeopathic, and 1 drug for further processing (openFDA NDC).
- Compounding. Oxytocin isn’t named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026 (FDA document). We searched the web for an FDA warning letter about an oxytocin nasal spray and found none; we did not search the FDA’s warning-letter database itself.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides (Reuters, 2026).
- Other countries. We did not check how other countries regulate nasal oxytocin.
- Research-use vials. Products labeled “research use only” aren’t approved for use in people.
- Sport. We searched a national copy of the World Anti-Doping Agency’s 2026 Prohibited List and found no mention of oxytocin. Its peptide-hormone class lists examples “including, but not limited to,” so check the current list before relying on this (WADA, 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- Which product the claim is about. The approved use is an injection given in a hospital. Nasal sprays have no FDA approval, and results from one don’t carry to the other.
- Whether the biggest trials are named. A page that cites small positive autism or weight trials without the 290-child and 61-adult trials has left out the largest results.
- Single dose or repeated use. Many lab findings come from one dose in healthy men. Trials of weeks of use mostly found no benefit or small ones.
- Scales or outcomes. Parent-rated social scales, mood questionnaires and brain scans aren’t the same as weight, symptoms or a diagnosis.
- Cited studies. One seller page we read credited oxytocin with lowering cholesterol, shifting the gut microbiome and reducing neuroinflammation and cited no study for any of it. Check that each claim names a trial and says who was in it.
- “FDA-approved.” Ask for what: labor and bleeding after birth, by vein.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
Twenty-nine trials of oxytocin outside labor and delivery are open or about to open, in PTSD, schizophrenia, autism, pain after surgery and more: see the list, with sponsor, phase, size and registry links.
Already under way: 2 active, not recruiting and 7 finished with no results posted.
What’s still unknown
- Whether nasal oxytocin works for any condition: the biggest trials in autism and obesity were negative, and the rest are small or mixed.
- How much of a nasal dose reaches the brain, and whether effects come from the brain or from the rest of the body.
- Whether weeks or months of use are safe; the longest registered trial of nasal oxytocin we found runs 12 months, in children.
- Why trials with more women found larger effects, and whether the dose or the way it is sprayed explains differences between trials.
- What is in nasal products sold online or compounded; we found no analysis.
- The results of registered trials in PTSD, borderline personality disorder, schizophrenia with therapy, pain after surgery and other uses, listed below.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Oxytocin. We recheck every month. Last checked Nov 15, 2026.
Flagged studies that mention Oxytocin
| Study | What it was about | Status |
|---|---|---|
| Tolba et al., 2018 | Management of Spontaneous Labor in Primigravidae: Labor Scale versus WHO Partograph (SLiP Trial) Randomized Controlled Trial. | Retracted (2018) · notice |
| Hofmann et al., 2015 | Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies. | Retracted (2018) · notice |
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Seifer et al., 1985 | J Reprod Med | No retraction or concern |
| Fewtrell et al., 2006 | Arch Dis Child Fetal Neonatal Ed | No retraction or concern |
| De Dreu et al., 2011 | Proc Natl Acad Sci U S A | No retraction or concern |
| MacDonald et al., 2011 | Psychoneuroendocrinology | No retraction or concern |
| Wudarczyk et al., 2013 | Curr Opin Psychiatry | No retraction or concern |
| Striepens et al., 2013 | Sci Rep | No retraction or concern |
| Behnia et al., 2014 | Horm Behav | No retraction or concern |
| Leng and Ludwig, 2016 | Biol Psychiatry | No retraction or concern |
| Yatawara et al., 2016 | Mol Psychiatry | No retraction or concern |
| Nave et al., 2015 | Perspect Psychol Sci | No retraction or concern |
| Torloni et al., 2016 | BJOG | No retraction or concern |
| Muin et al., 2017 | Fertil Steril | No retraction or concern |
| Lee et al., 2018 | Mol Psychiatry | No retraction or concern |
| Valstad et al., 2017 | Neurosci Biobehav Rev | No retraction or concern |
| Cai et al., 2018 | Psychiatry Clin Neurosci | No retraction or concern |
| Kruger et al., 2018 | J Clin Psychopharmacol | No retraction or concern |
| Widmer et al., 2018 | N Engl J Med | No retraction or concern |
| Boll et al., 2020 | Neuropharmacology | No retraction or concern |
| Lee et al., 2020 | Nat Commun | No retraction or concern |
| Flynn et al., 2021 | Int J Gynaecol Obstet | No retraction or concern |
| Huang et al., 2021 | Neurosci Biobehav Rev | No retraction or concern |
| Sabe et al., 2021 | Int J Neuropsychopharmacol | No retraction or concern |
| Espinoza et al., 2021 | J Am Med Dir Assoc | No retraction or concern |
| Chen et al., 2021 | Clin Nutr | No retraction or concern |
| Sikich et al., 2021 | N Engl J Med | No retraction or concern |
| Guastella et al., 2023 | Mol Psychiatry | No retraction or concern |
| Daniels et al., 2023 | Mol Autism | No retraction or concern |
| Maguire et al., 2024 | Psychoneuroendocrinology | No retraction or concern |
| Plessow et al., 2024 | NEJM Evid | No retraction or concern |
| Gallos et al., 2025 | Cochrane Database Syst Rev | No retraction or concern |
| Flanagan et al., 2026 | BJOG | No retraction or concern |
| Schneider et al., 2026 | JAMA Psychiatry | No retraction or concern |
| Galbiati et al., 2026 | Int J Obes (Lond) | No retraction or concern |
| Bonnieux et al., 2026 | Neurosci Biobehav Rev | No retraction or concern |
| Roof et al., 2026 | Clin Ther | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is oxytocin?
Oxytocin is a peptide hormone of nine amino acids, made in the hypothalamus and released by the pituitary gland. It makes the uterus contract in birth and moves milk in nursing, and it acts in the brain (Wudarczyk et al., 2013). Synthetic oxytocin is an FDA-approved injection (Pitocin label).
What does oxytocin do in the body?
In the blood it triggers uterine contractions and milk letdown, and it has an antidiuretic effect on the kidneys. In the brain it acts on circuits for social, sexual and motivational behavior (Wudarczyk et al., 2013; Pitocin label).
Does oxytocin nasal spray work?
It depends on the use, and the largest trials were negative. In 290 children and teenagers with autism, 24 weeks of spray did no better than placebo, and in 61 adults with obesity, 8 weeks didn’t change weight. A 2026 analysis of 42 trials in mental disorders found a small effect that was not statistically significant (Sikich et al., 2021; Plessow et al., 2024; Bonnieux et al., 2026).
Is oxytocin nasal spray FDA-approved?
No. Drugs@FDA lists three oxytocin applications and all are injections, and the Pitocin label covers intravenous use in a hospital (openFDA Drugs@FDA; Pitocin label).
Can oxytocin treat autism?
The largest trial, 290 children and teenagers over 24 weeks, found no difference from placebo. Smaller trials and a meta-analysis that included uncontrolled studies found gains on parent-rated social scales, and one trial hinted at a benefit in children aged 3 to 5 (Sikich et al., 2021; Yatawara et al., 2016; Guastella et al., 2023; Huang et al., 2021).
Does oxytocin help you lose weight?
Not in the largest trial. In 61 adults with obesity, 8 weeks of nasal oxytocin didn’t change weight (0.20 against 0.26 kg), though calories eaten at a test meal fell by 152 kcal compared with placebo (Plessow et al., 2024).
Does oxytocin make you trust people?
The finding that nasal oxytocin raises trust has not replicated well (Nave et al., 2015). In five experiments in men it increased favoritism toward their own group and, to a lesser extent, derogation of outsiders (De Dreu et al., 2011).
Does oxytocin improve sex?
Results are mixed and small. In 27 healthy women it had no effect on drive, arousal or vaginal blood flow, and in 29 couples it raised orgasm intensity and contentment with small to moderate effects but didn’t change drive or arousal (Kruger et al., 2018; Behnia et al., 2014).
Does a nasal spray get oxytocin into the brain?
Some does. Oxytocin rose in human spinal fluid after a 24 IU nasal dose and reached brain tissue in macaques, but a review argues very little of a nasal dose reaches spinal fluid and blood levels rise instead (Striepens et al., 2013; Lee et al., 2020; Leng and Ludwig, 2016).
What are the side effects of oxytocin?
In short nasal-spray trials side effects weren’t different from placebo, and the most common were nasal discomfort, irritability and tiredness. The injection’s label warns of water intoxication, and a 1985 case report describes seizures after heavy nasal-spray use (MacDonald et al., 2011; Cai et al., 2018; Pitocin label; Seifer et al., 1985).
What is the difference between oxytocin and Pitocin?
Pitocin is a brand of FDA-approved synthetic oxytocin injection, given by vein in a hospital to start or strengthen labor for a medical reason and to control bleeding after birth. It is the same hormone, made in the lab (Pitocin label).
What is the difference between oxytocin and carbetocin?
Carbetocin is a different drug: an oxytocin analogue with a longer half-life. Heat-stable carbetocin was noninferior to oxytocin for one bleeding outcome in 29,645 women, but noninferiority wasn’t shown for blood loss of 1,000 mL or more (Roof et al., 2026; Widmer et al., 2018).
Is oxytocin addictive?
We found no trial that tested it for addiction. A review found no detectable subjective changes in people given nasal oxytocin in research, and another says there is no evidence to date that it has addictive properties but that dosing and long use need study (MacDonald et al., 2011; Wudarczyk et al., 2013).
Are there oxytocin clinical trials recruiting?
Yes. 29 trials of oxytocin outside labor and delivery are recruiting or about to, from PTSD and schizophrenia to pain after surgery, and 26 more record oxytocin in labor, delivery and cesarean care. See the list with sponsors and registry links.
Sources
- Wudarczyk OA, et al. Could intranasal oxytocin be used to enhance relationships? Research imperatives, clinical policy, and ethical considerations. Curr Opin Psychiatry. 2013;26(5):474-484. PubMed 23880593
- Striepens N, et al. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep. 2013;3:3440. PubMed 24310737
- Leng G, et al. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry. 2016;79(3):243-50. PubMed 26049207
- Lee MR, et al. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Mol Psychiatry. 2018;23(1):115-122. PubMed 28289281
- Lee MR, et al. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nat Commun. 2020;11(1):2783. PubMed 32494001
- Valstad M, et al. The correlation between central and peripheral oxytocin concentrations: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;78:117-124. PubMed 28442403
- Sikich L, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med. 2021;385(16):1462-1473. PubMed 34644471
- Guastella AJ, et al. The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Mol Psychiatry. 2023;28(2):834-842. PubMed 36302965
- Yatawara CJ, et al. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21(9):1225-31. PubMed 26503762
- Daniels N, et al. Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial. Mol Autism. 2023;14(1):16. PubMed 37081454
- Cai Q, et al. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry Clin Neurosci. 2018;72(3):140-151. PubMed 29232031
- Huang Y, et al. Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis. Neurosci Biobehav Rev. 2021;122:18-27. PubMed 33400920
- Bonnieux J, et al. Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials. Neurosci Biobehav Rev. 2026;187:106749. PubMed 42134427
- Sabe M, et al. Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials. Int J Neuropsychopharmacol. 2021;24(8):601-613. PubMed 33890987
- Maguire S, et al. A phase II randomised controlled trial of intranasal oxytocin in anorexia nervosa. Psychoneuroendocrinology. 2024;164:107032. PubMed 38520886
- Plessow F, et al. Intranasal Oxytocin for Obesity. NEJM Evid. 2024;3(5):EVIDoa2300349. PubMed 38815173
- Chen CY, et al. Effects of intranasal oxytocin in food intake and craving: A meta-analysis of clinical trials. Clin Nutr. 2021;40(10):5407-5416. PubMed 34600216
- Galbiati F, et al. Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity. Int J Obes (Lond). 2026;50(7):1508-1514. PubMed 41951782
- Espinoza SE, et al. Intranasal Oxytocin Improves Lean Muscle Mass and Lowers LDL Cholesterol in Older Adults with Sarcopenic Obesity: A Pilot Randomized Controlled Trial. J Am Med Dir Assoc. 2021;22(9):1877-1882. PubMed 34029521
- Kruger THC, et al. Effects of Intranasal Oxytocin Administration on Sexual Functions in Healthy Women: A Laboratory Paradigm. J Clin Psychopharmacol. 2018;38(3):239-242. PubMed 29596150
- Behnia B, et al. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav. 2014;65(3):308-18. PubMed 24503174
- Muin DA, et al. Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study. Fertil Steril. 2017;107(3):781-787.e3. PubMed 28189292
- Schneider E, et al. Intranasal Oxytocin and Physical Intimacy for Dermatological Wound Healing and Neuroendocrine Stress: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(2):118-127. PubMed 41222549
- Nave G, et al. Does Oxytocin Increase Trust in Humans? A Critical Review of Research. Perspect Psychol Sci. 2015;10(6):772-89. PubMed 26581735
- De Dreu CK, et al. Oxytocin promotes human ethnocentrism. Proc Natl Acad Sci U S A. 2011;108(4):1262-6. PubMed 21220339
- Boll S, et al. Pain-modulating effects of oxytocin in patients with chronic low back pain. Neuropharmacology. 2020;171:108105. PubMed 32298704
- Flynn MJ, et al. Intranasal oxytocin as a treatment for chronic pelvic pain: A randomized controlled feasibility study. Int J Gynaecol Obstet. 2021;152(3):425-432. PubMed 33112417
- Fewtrell MS, et al. Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):F169-74. PubMed 16223754
- MacDonald E, et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36(8):1114-26. PubMed 21429671
- Seifer DB, et al. Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report. J Reprod Med. 1985;30(3):225-8. PubMed 3923190
- Roof E, et al. Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study. Clin Ther. 2026;48(11):1089-1098. PubMed 42486751
- Widmer M, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med. 2018;379(8):743-752. PubMed 29949473
- Gallos ID, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2025;4(4):CD011689. PubMed 40237648
- Flanagan M, et al. The Effectiveness of Oxytocin for Preventing Postpartum Haemorrhage: An Individual Participant Data Meta-Analysis. BJOG. 2026;133(1):24-33. PubMed 40665776
- Torloni MR, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076-2086. PubMed 27006180
- ClinicalTrials.gov. SOARS-B, NCT01944046, and the 55 oxytocin records listed or counted on the recruiting-trials page, November 15, 2026. Search
- U.S. Food and Drug Administration. Pitocin (oxytocin injection) prescribing information, label effective May 6, 2026. DailyMed
- U.S. Food and Drug Administration. openFDA Drugs@FDA: search for oxytocin, November 15, 2026 (three applications, all injections). openFDA
- U.S. Food and Drug Administration. openFDA drug listings (NDC): 60 listings name oxytocin, November 15, 2026. openFDA NDC
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (oxytocin not named). FDA document
- World Anti-Doping Agency. 2026 Prohibited List, searched for oxytocin on November 16, 2026 in a national copy of the list because the WADA file would not download; no mention found. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: Oxytocin (CID 439302). PubChem
Last reviewed Nov 15, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.